Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM6B | O15054 | 1/20 | 0.44 |
| ▸ | TET3 | O43151 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.44 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.44 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.44 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31166004 | 0.89 | AR (0.43) | ARCYP17A1ATRSREBF2CA12 | |
| SCHEMBL4597222 | 0.88 | CYP17A1 (0.46) | ARCYP17A1ATRSREBF2CA12 | |
| SCHEMBL29530078 | 0.88 | CYP17A1 (0.46) | ARCYP17A1ATRSREBF2CA12 | |
| SCHEMBL29187149 | 0.87 | AR (0.60) | ARCYP17A1ATRALDH1A1SREBF2 | |
| SCHEMBL31116575 | 0.85 | AR (0.45) | ARCYP17A1ATRALDH1A1SREBF2 | |
| SCHEMBL22670384 | 0.85 | AR (0.48) | ARCYP17A1ATRSREBF2CA12 | |
| SCHEMBL1501665 | 0.82 | SMARCA2 (0.57) | ARCYP17A1ATRCA12CA1 | |
| SCHEMBL16055308 | 0.82 | SMARCA2 (0.57) | CYP17A1ATRCA12CA1CA9 | |
| SCHEMBL30293080 | 0.82 | SMARCA2 (0.57) | CYP17A1ATRCA12CA1CA9 | |
| SCHEMBL17512706 | 0.81 | TOP2A (0.43) | CYP17A1EGLN2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2958910-B1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LTD (GB) | 2016-08-03 | — | — | EP | disclosed |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| EP-2958910-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | Domainex Limited (GB) | 2015-12-30 | — | — | EP | disclosed |
| CN-105189480-A | Pyrimidine compounds useful in the treatment of disorders mediated by the IKK and/or TBK-1 mechanism | DOMAINEX LTD | 2015-12-23 | — | — | CN | disclosed |
| WO-2014128486-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | TBK1, TBKBP1, TYMS | AR 4510/4885CYP17A1 4217/4885ATR 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.